We are live on ! Find out more
CCCC icon

C4 Therapeutics
CCCC

120 hedge funds and large institutions have $117M invested in C4 Therapeutics in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 36 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,313% more call options, than puts

Call options by funds: $193K | Put options by funds: $8K

22% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 36

18% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 17

3% more funds holding

Funds holding: 117 → 120 (+3)

3.88% less ownership

Funds ownership: 80.09% → 76.21% (-3.9%)

49% less capital invested

Capital invested by funds: $229M → $117M (-$112M)

Holders
120
Holders Change
+3
Holders Change %
+2.56%
% of All Funds
1.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
44
Reduced
36
Closed
17
Calls
$193K
Puts
$8K
Net Calls
+$185K
Net Calls Change
+$6K

Top Buyers

Rank Fund Capital Flow
1
TCM
TCG Crossover Management
California
+$7.36M
2
ACH
ArrowMark Colorado Holdings
Colorado
+$3.4M
3
AQR Capital Management
AQR Capital Management
Connecticut
+$1.95M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.73M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.49M

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$16.6M
2
State Street
State Street
Massachusetts
-$9.85M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$4.28M
4
DCM
Driehaus Capital Management
Illinois
-$2.04M
5
Rafferty Asset Management
Rafferty Asset Management
New York
-$1.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
SO
101
STRS Ohio
Ohio
$17K – – –
AB
102
Amalgamated Bank
New York
$13K -$5.74K -975 -19%
TRCT
103
Tower Research Capital (TRC)
New York
$12K +$13.8K +2,339 +156%
QT
104
Quantbot Technologies
New York
$11.1K -$9.27K -1,574 -31%
Federated Hermes
105
Federated Hermes
Pennsylvania
$10.9K -$44.8K -7,614 -69%
AIP
106
Ameritas Investment Partners
Nebraska
$9.3K – – –
Amundi
107
Amundi
France
$9.19K – – –
Royal Bank of Canada
108
Royal Bank of Canada
Ontario, Canada
$9K -$31.5K -5,353 -65%
Northwestern Mutual Wealth Management
109
Northwestern Mutual Wealth Management
Wisconsin
$8.25K – – –
TIM
110
Tortoise Investment Management
New York
$4.71K – – –
Citigroup
111
Citigroup
New York
$4.46K -$456K -77,388 -98%
MLICM
112
Metropolitan Life Insurance Company (MetLife)
New York
$3.48K -$8.69K -1,476 -57%
FHA
113
First Horizon Advisors
Tennessee
$2.9K -$553 -94 -9%
CUAMC
114
China Universal Asset Management Company
China
$2.09K +$989 +168 +34%
Nisa Investment Advisors
115
Nisa Investment Advisors
Missouri
$2K -$15.1K -2,562 -83%
PSB
116
Piscataqua Savings Bank
New Hampshire
$1.88K – – –
DFCM
117
Dark Forest Capital Management
Puerto Rico
$421 +$789 +134 New
Commonwealth Equity Services
118
Commonwealth Equity Services
Massachusetts
$48 +$7.14K +1,212 +9%
RI
119
RTW Investments
New York
– -$16.6M -2,819,472 Closed
DCM
120
Driehaus Capital Management
Illinois
– -$2.04M -345,969 Closed
Rafferty Asset Management
121
Rafferty Asset Management
New York
– -$1.05M -177,858 Closed
JF
122
Jump Financial
Illinois
– -$212K -36,000 Closed
AGM
123
Alpine Global Management
New York
– -$110K -18,574 Closed
ACM
124
Aquatic Capital Management
Illinois
– -$80K -13,800 Closed
Rockefeller Capital Management
125
Rockefeller Capital Management
New York
– -$69K -11,859 Closed
2 3 4
5
6

CCCC Hedge Fund Activity: Q1 2023 in Review

120 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q1 2023, worth a combined $117M — down 49% from $229M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new CCCC positions and 17 closed out — a net gain of 3 holders — while 44 added to existing stakes and 36 trimmed.

The largest buyer was TCG Crossover Management, opening a new position worth an estimated $7.36M. The largest seller was RTW Investments, exiting entirely with an estimated $16.6M sold.

  • 120 institutional investors held C4 Therapeutics (CCCC) as of Q1 2023, up from 117 in Q4 2022.
  • Funds reported $117M of C4 Therapeutics stock for Q1 2023, down 49% quarter-over-quarter.
  • 20 funds opened new C4 Therapeutics positions in Q1 2023 and 17 closed out, a net change of +3 holders.
  • The largest C4 Therapeutics buyer in Q1 2023 was TCG Crossover Management, an estimated $7.36M added.
  • The largest C4 Therapeutics seller in Q1 2023 was RTW Investments, an estimated $16.6M sold.

Based on aggregated 13F filings for Q1 2023.